A detailed history of Ameriprise Financial Inc transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 763,874 shares of ACAD stock, worth $13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
763,874
Previous 742,646 2.86%
Holding current value
$13 Million
Previous $12.1 Million 2.58%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.14 - $19.14 $321,391 - $406,303
21,228 Added 2.86%
763,874 $11.8 Million
Q2 2024

Aug 14, 2024

BUY
$14.62 - $18.42 $6,769 - $8,528
463 Added 0.06%
742,646 $12.1 Million
Q1 2024

May 15, 2024

BUY
$17.79 - $30.86 $1.69 Million - $2.93 Million
95,071 Added 14.69%
742,183 $13.7 Million
Q4 2023

Feb 14, 2024

BUY
$20.78 - $31.77 $1.4 Million - $2.15 Million
67,605 Added 11.67%
647,112 $20.3 Million
Q3 2023

Nov 14, 2023

BUY
$20.84 - $33.47 $238,847 - $383,599
11,461 Added 2.02%
579,507 $12.1 Million
Q2 2023

Aug 14, 2023

SELL
$17.8 - $25.65 $221,236 - $318,803
-12,429 Reduced 2.14%
568,046 $13.6 Million
Q1 2023

May 15, 2023

BUY
$16.32 - $20.92 $933,161 - $1.2 Million
57,179 Added 10.93%
580,475 $10.9 Million
Q4 2022

Feb 14, 2023

SELL
$14.2 - $18.63 $5.77 Million - $7.57 Million
-406,511 Reduced 43.72%
523,296 $8.33 Million
Q3 2022

Nov 14, 2022

SELL
$14.11 - $18.27 $215,219 - $278,672
-15,253 Reduced 1.61%
929,807 $15.2 Million
Q2 2022

Aug 15, 2022

SELL
$13.01 - $27.22 $1.75 Million - $3.66 Million
-134,481 Reduced 12.46%
945,060 $13.3 Million
Q1 2022

May 16, 2022

SELL
$20.94 - $27.5 $1.65 Million - $2.17 Million
-78,757 Reduced 6.8%
1,079,541 $26.1 Million
Q4 2021

Feb 14, 2022

BUY
$16.79 - $27.09 $495,607 - $799,642
29,518 Added 2.62%
1,158,298 $27 Million
Q3 2021

Nov 15, 2021

SELL
$15.78 - $24.77 $2.68 Million - $4.21 Million
-169,958 Reduced 13.09%
1,128,780 $18.8 Million
Q2 2021

Aug 16, 2021

SELL
$19.4 - $27.42 $22 Million - $31.1 Million
-1,135,313 Reduced 46.64%
1,298,738 $31.7 Million
Q1 2021

May 17, 2021

BUY
$25.02 - $54.99 $29.2 Million - $64.3 Million
1,168,541 Added 92.34%
2,434,051 $62.8 Million
Q4 2020

Feb 12, 2021

BUY
$41.04 - $56.79 $2.03 Million - $2.81 Million
49,503 Added 4.07%
1,265,510 $67.7 Million
Q3 2020

Nov 16, 2020

SELL
$36.42 - $57.0 $34.6 Million - $54.2 Million
-950,967 Reduced 43.88%
1,216,007 $50.2 Million
Q2 2020

Aug 14, 2020

BUY
$39.26 - $52.73 $22.6 Million - $30.3 Million
574,958 Added 36.12%
2,166,974 $105 Million
Q1 2020

May 15, 2020

BUY
$31.65 - $46.87 $22.6 Million - $33.5 Million
713,916 Added 81.3%
1,592,016 $67.3 Million
Q4 2019

Feb 14, 2020

SELL
$36.21 - $51.4 $4.43 Million - $6.29 Million
-122,394 Reduced 12.23%
878,100 $37.6 Million
Q3 2019

Nov 14, 2019

BUY
$22.22 - $44.01 $11.8 Million - $23.4 Million
530,622 Added 112.93%
1,000,494 $36 Million
Q2 2019

Aug 14, 2019

SELL
$23.32 - $28.12 $1.46 Million - $1.77 Million
-62,797 Reduced 11.79%
469,872 $12.6 Million
Q1 2019

May 15, 2019

BUY
$16.17 - $27.38 $2.72 Million - $4.6 Million
168,178 Added 46.14%
532,669 $14.3 Million
Q4 2018

Feb 14, 2019

SELL
$14.32 - $22.92 $6,716 - $10,749
-469 Reduced 0.13%
364,491 $5.89 Million
Q3 2018

Nov 14, 2018

SELL
$13.03 - $21.81 $7.52 Million - $12.6 Million
-577,268 Reduced 61.27%
364,960 $7.56 Million
Q2 2018

Aug 14, 2018

BUY
$15.07 - $22.34 $1.07 Million - $1.58 Million
70,908 Added 8.14%
942,228 $14.4 Million
Q1 2018

May 15, 2018

BUY
$22.47 - $32.33 $570,288 - $820,535
25,380 Added 3.0%
871,320 $19.6 Million
Q4 2017

Feb 12, 2018

SELL
$26.84 - $39.14 $1.24 Million - $1.8 Million
-46,066 Reduced 5.16%
845,940 $25.5 Million
Q3 2017

Nov 07, 2017

BUY
$29.49 - $38.37 $26.3 Million - $34.2 Million
892,006
892,006 $33.6 Million

Others Institutions Holding ACAD

About ACADIA PHARMACEUTICALS INC


  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.76B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Ameriprise Financial Inc Portfolio

Follow Ameriprise Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.